Home › Companies › AMLX

Amylyx Pharmaceuticals

Market cap $3.54B 128.6M shares (10-Q, Oct 26, 2026) × $27.52 close Nov 17, 2026

Most recent annual filing: 2026-03-03

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. avexitide PBH NDA filingby end of 2026avexitide PBH NDA filing, by end of 2026, material
  2. AMX0318 IND filing2027AMX0318 IND filing, 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Technology platforms

Second Gubra Collaboration · Gubra

Research collaboration with Gubra A/S to identify potential development candidates for a rare endocrine disease of high unmet need; no specific candidate code disclosed.

Discontinued (1)

Capital (as filed)

Cash
$240M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$528M Sep 30, 2026
Operating cash flow
−$33.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$768M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on Amylyx Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Amylyx Pharmacueticals (AMLX) - Scientific Deep Dive for Avexitide and Pipeline Products Avexitide's mechanistically sound GLP-1 antagonism in PBH is compelling, but small Phase 2 data and legal overhang warrant watching rather than buying ahead of the Q3 2026 Phase 3 readout.
  2. Watch UPDATE: Amylyx Pharmaceuticals (AMLX) - The Clock Starts Now LUCIDITY enrollment completion removes execution risk and locks in the Q3 2026 timeline, but the thesis remains a watch-list binary event play with no change to stance.
  3. Watch UPDATE: Amylyx Pharmaceuticals (AMLX) — The Quiet Tells Before the Binary Legal overhang largely lifting, EAP launch signals management confidence, and balance sheet intact, but the Q3 binary still dominates and sizing should reflect a potential 50% downside on a miss.
  4. Watch UPDATE: Amylyx Pharmaceuticals (AMLX) - The Binary Has a Date LUCIDITY topline is now dated for late August/early September with all execution risk retired, but the stock's +59% run has pulled forward much of the upside, making the risk/reward closer to a fair coin flip than the original asymmetric setup.
  5. Watch UPDATE: Amylyx Pharmaceuticals (AMLX) - The Alarm Goes Off Tomorrow LUCIDITY topline drops at 8:00 a.m. ET tomorrow; the -11.4% pre-event drawdown modestly improves entry math but the binary distribution is unchanged and positioning should reflect a sub-24-hour coin flip.
  6. Speculative buy speculative UPDATE: Amylyx Pharmaceuticals (AMLX) - The Coin Landed Heads LUCIDITY hit its primary endpoint with a 55% placebo-adjusted reduction (p=0.000003) and all secondaries cleared, retiring clinical risk; remaining risk is commercial and manufacturing, making this a speculative buy at the post-data price.
  7. Speculative buy speculative UPDATE: Amylyx Pharmaceuticals (AMLX) - The $500 Million Vote of Confidence The offering upsized to $500M and priced above the prior close, signaling oversubscription and institutional demand; the war chest now exceeds $720M, but CMO agreements are not yet signed and the easy money is behind us.
  8. Speculative buy speculative UPDATE: Amylyx Pharmaceuticals (AMLX) - The Factory Gets a Name Bachem supply agreement signed and Polypeptide at term sheet with $30M committed partially retires the CMC risk I graded High; stock trades 22% below deal price, improving the asymmetry versus August.
  9. Speculative buy speculative UPDATE: Amylyx Pharmaceuticals (AMLX) - The Fine Print Holds Up Full LUCIDITY data at ObesityWeek confirms the topline with 0.55 vs 1.24 events/week and all prespecified secondaries hit; an 8% post-data dip on confirmatory results may be worth a look for those waiting on the full dataset.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (36)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 15, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)